01
Core facts
- Entity type
- Organization
- Legal name
- Calico Life Sciences LLC[2]first-party sourceGlobal Privacy PolicyCalicoCalico’s current privacy policy identifies the responsible organization as Calico Life Sciences LLC.CheckedOpen original source
- Headquarters
- South San Francisco, California, United States[3]first-party sourceContact UsCalicoCalico’s current contact page lists its office in South San Francisco, California.CheckedOpen original source
- Country
- United States[3]first-party sourceContact UsCalicoCalico’s official contact page gives its office in South San Francisco, California, United States.CheckedOpen original source
- Headquarters address
- 1170 Veterans Blvd, South San Francisco, CA 94080, United States[3]first-party sourceContact UsCalicoCalico’s current contact page lists 1170 Veterans Boulevard, South San Francisco, California 94080 as its office address.CheckedOpen original source
- Official website
- calicolabs.com[1]first-party sourceCalico — HomeCalicoCalico’s official homepage presents its research, clinical programmes, company information and navigation on the calicolabs.com domain.CheckedOpen original source
02
What is Calico?[5]first-party sourceFosigotifator Granted FDA Breakthrough Therapy DesignationCalicoCalico’s June 2026 release documents one investigational therapy program and explicitly states fosigotifator is not approved by any regulatory authority.CheckedOpen original source [1]first-party sourceCalico — HomeCalicoCalico’s homepage describes basic research, advanced computational biology, machine learning, drug development and clinical programmes, and distinguishes potential medicines from approved treatments.CheckedOpen original source [6]first-party sourceResearch & TechnologyCalicoCalico’s Research & Technology page describes basic research in model organisms and human genetic data, computational methods, and translation toward interventions.CheckedOpen original source
Calico combines basic research into aging biology with computational methods and drug development. Its published approach studies model systems and human data, while its clinical-stage programmes investigate potential therapies for age-related and other serious diseases. These programmes remain investigational unless separately approved.
03
History
Calico launched in 2013 with support from Google to study the biology of aging and translate research into potential medicines.[7]first-party sourceOur Story: Taking a long-term view on tackling aging and increasing healthspanCalicoCalico’s official company history says it launched in 2013 with support from Google and describes the initial dual mission of aging-biology research and translation into medicines.CheckedOpen original source
Calico says its own laboratories became operational in 2015.[7]first-party sourceOur Story: Taking a long-term view on tackling aging and increasing healthspanCalicoCalico’s company history states that its own labs became operational in 2015 after establishing research-partner collaborations.CheckedOpen original source
In May 2024, Calico and the Broad Institute extended their collaboration through September 2029, adding a focus on age-related neurodegeneration.[8]first-party sourceCalico and Broad Institute Extend CollaborationCalicoThe joint announcement states that the renewed agreement runs through September 2029 and adds age-related neurodegeneration to ongoing aging-biology and early-stage drug-discovery work.CheckedOpen original source
In May 2026, Calico and Nexo announced a multi-target collaboration to discover and develop small-molecule therapies for challenging disease targets.[9]first-party sourceCalico and Nexo CollaborationCalicoThe companies’ May 21, 2026 announcement says they will jointly pursue targets nominated by Calico, using Nexo’s chemistry platform; Calico will lead further development and commercialization of resulting programmes.CheckedOpen original source
04
Contributions and work
- Collaboration Model
- Calico works with external biopharmaceutical and academic organizations on research and drug discovery.[6]first-party sourceResearch & TechnologyCalicoCalico’s research page describes collaboration with external biopharmaceutical companies and academic institutions as part of its research approach.CheckedOpen original source
- Computational Biology
- Calico combines biology research with advanced computing, machine learning, computer vision, and analysis of genotypic and phenotypic data.[6]first-party sourceResearch & TechnologyCalicoCalico’s technology section describes machine learning, software engineering, data science, advanced computer vision and analysis of genotypic and phenotypic data in its research.CheckedOpen original source
- Focus
- Calico studies the biology of aging and age-related diseases, with work spanning basic research and translation toward potential interventions.[6]first-party sourceResearch & TechnologyCalicoCalico describes studying aging biology and age-related disease and translating discoveries into potential interventions.CheckedOpen original source
- Model Systems
- Calico’s basic-research programme studies aging in yeast, C. elegans, mice, and human cells and tissues, alongside human genetic datasets.[6]first-party sourceResearch & TechnologyCalicoCalico lists yeast, C. elegans, mice, human cells and tissues as model systems and says computational researchers also use available human genetic datasets.CheckedOpen original source
- Translation
- Calico links basic research with therapeutic discovery and clinical development for diseases associated with aging.[1]first-party sourceCalico — HomeCalicoCalico describes moving from basic research and computational biology through drug development toward potential clinical impact; it also lists clinical research and ongoing therapy programmes.CheckedOpen original source
05
Products
- Drug Development
- Drug development aimed at translating biological findings into potential treatments.[1]first-party sourceCalico — HomeCalicoThe official Calico site describes drug development and translating biological insights into potential treatments.CheckedOpen original source
- Fosigotifator
- Fosigotifator (ABBV-CLS-7262) is an investigational eIF2B activator developed by Calico for vanishing white matter disease; it is not an approved medicine.[5]first-party sourceFosigotifator Granted FDA Breakthrough Therapy DesignationCalicoCalico’s June 23, 2026 release identifies fosigotifator as an investigational eIF2B activator it developed for vanishing white matter disease and explicitly states it has not been approved by a regulatory authority.CheckedOpen original source
- Fosigotifator Clinical Stage
- Calico reported fosigotifator in a Phase 1b/2 clinical trial for vanishing white matter disease as of June 23, 2026.[5]first-party sourceFosigotifator Granted FDA Breakthrough Therapy DesignationCalicoThe company’s dated June 23, 2026 release says the investigational drug was in a Phase 1b/2 trial evaluating safety, tolerability, pharmacokinetics and exploratory efficacy.CheckedOpen original source
- Fosigotifator Regulatory Status
- The U.S. FDA granted fosigotifator Breakthrough Therapy Designation for vanishing white matter disease on June 23, 2026; the designation is not marketing approval.[5]first-party sourceFosigotifator Granted FDA Breakthrough Therapy DesignationCalicoCalico announced the FDA designation on June 23, 2026 and separately states fosigotifator remains investigational and unapproved by any regulatory authority.CheckedOpen original source
06
Leadership
- Chief Business Officer
- Jonathan W. Lewis is Calico’s Chief Business Officer.[10]first-party sourcePeople and LeadershipCalicoCalico’s current leadership roster lists Jonathan W. Lewis as Chief Business Officer.CheckedOpen original source
- Chief Financial Officer
- John Whiting is Calico’s Chief Financial Officer.[10]first-party sourcePeople and LeadershipCalicoCalico’s current leadership roster lists John Whiting as Chief Financial Officer.CheckedOpen original source
- Founder Ceo
- Arthur D. Levinson is Calico’s Founder and Chief Executive Officer.[10]first-party sourcePeople and LeadershipCalicoCalico’s current leadership roster identifies Arthur D. Levinson as Founder & CEO; his profile says he co-founded Calico and was named CEO in September 2013.CheckedOpen original source
- Head Discovery Technologies
- Dan Eaton is Calico’s Head of Discovery Technologies.[10]first-party sourcePeople and LeadershipCalicoCalico’s current leadership roster lists Dan Eaton as Head of Discovery Technologies.CheckedOpen original source
- Head Drug Discovery Development Sciences
- Philip Kym leads Drug Discovery and Development Sciences at Calico.[10]first-party sourcePeople and LeadershipCalicoCalico’s current leadership roster lists Philip Kym as Head of Drug Discovery and Development Sciences.CheckedOpen original source
- Head Human Biology Genetics
- Calico announced Joe Arron as Head of Human Biology and Genetics in February 2026.[11]first-party sourceCalico Appoints Joseph R. Arron as Head of Human Biology and GeneticsCalicoCalico’s February 5, 2026 appointment announcement identifies Joseph R. Arron as Head of Human Biology and Genetics.CheckedOpen original source
- Head Research Development
- Joe Arron is Calico’s Head of Research & Development.[10]first-party sourcePeople and LeadershipCalicoCalico’s current leadership roster lists Joe Arron as Head of Research & Development.CheckedOpen original source
- Vice President Aging Research
- Cynthia Kenyon is Calico’s Vice President of Aging Research.[10]first-party sourcePeople and LeadershipCalicoCalico’s current leadership roster lists Cynthia Kenyon as Vice President, Aging Research.CheckedOpen original source
08
Sources
Reference numbers stay stable across this page and each source appears once, ordered by first visible use.
- Calico — Home
Calico · first-party source
- Global Privacy Policy
Calico · first-party source
- Contact Us
Calico · first-party source
- Calico (Q14932155)
Wikidata · structured public data source
- Fosigotifator Granted FDA Breakthrough Therapy Designation
Calico · first-party source
- Research & Technology
Calico · first-party source
- Our Story: Taking a long-term view on tackling aging and increasing healthspan
Calico · first-party source
- Calico and Broad Institute Extend Collaboration
Calico · first-party source
- Calico and Nexo Collaboration
Calico · first-party source
- People and Leadership
Calico · first-party source
- Calico Appoints Joseph R. Arron as Head of Human Biology and Genetics
Calico · first-party source
- Alphabet Inc. — Wikidata
Wikidata · structured public data source
Found something that needs review?
Suggest a correction